Clinical Trial Update: Sacituzumab Govitecan in Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating sacituzumab govitecan for recurrent glioblastoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Recurrent Glioblastoma | Phase 2 | Status: RECRUITING